NexImmune Overview
- Year Founded
-
2011
- Status
-
Out of Business
- Employees
-
72
- Latest Deal Type
-
Liquidation
NexImmune General Information
Description
NexImmune Inc is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body's T cells to generate an antigen-specific cell-mediated immune response with curative potential for the patient. It creates therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. The company has two product candidates in human trials: NEXI-001 in acute myeloid leukemia, or AML, and NEXI-002 in multiple myeloma, or MM.
Contact Information
Website
www.neximmune.comCorporate Office
- 9119 Gaither Road
- Gaithersburg, MD 20877
- United States
Corporate Office
- 9119 Gaither Road
- Gaithersburg, MD 20877
- United States
NexImmune Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 14. Bankruptcy: Liquidation | 27-Aug-2024 | Completed | Bankruptcy: Liquidation | |||
| 13. 2PO | 05-Feb-2024 | Completed | Generating Revenue | |||
| 12. IPO | 12-Feb-2021 | Completed | Clinical Trials - Phase 1 | |||
| 11. Later Stage VC | 31-Jan-2021 | Completed | Clinical Trials - Phase 1 | |||
| 10. Debt - PPP | 30-Apr-2020 | Completed | Clinical Trials - Phase 1 | |||
| 9. Later Stage VC (Series A3) | 27-Nov-2019 | Completed | Clinical Trials - Phase 1 | |||
| 8. Later Stage VC (Series A2) | 22-Feb-2019 | Completed | Clinical Trials - Phase 1 | |||
| 7. Later Stage VC (Series A) | 01-Jan-2018 | Completed | Clinical Trials - Phase 1 | |||
| 6. Buyout/LBO | 14-Feb-2017 | $5.25M | Completed | Clinical Trials - Phase 1 | ||
| 5. Early Stage VC | 13-Feb-2015 | $1.96M | $5.25M | Completed | Clinical Trials - Phase 1 |
NexImmune Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A-3 | ||||||||
| Series A-2 | ||||||||
| Series A | 121,735,303 | $0.000100 | $0.02 | $0.3 | $0.3 | 1x | $0.3 | 49.87% |
NexImmune Comparisons
Industry
Financing
Details
NexImmune Competitors (57)
One of NexImmune’s 57 competitors is Marengo Therapeutics, a Venture Capital-Backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Marengo Therapeutics | Venture Capital-Backed | Cambridge, MA | ||||
| Iovance Biotherapeutics | Corporation | San Carlos, CA | ||||
| Parvus Therapeutics | Venture Capital-Backed | South San Francisco, CA | ||||
| Kite Pharma | Formerly VC-backed | Santa Monica, CA | ||||
| Sorrento Therapeutics | Formerly VC-backed | San Diego, CA |
NexImmune Patents
NexImmune Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2024206207-A1 | Injectable artificial antigen presenting cells for immune therapy | Inactive | 24-Mar-2023 | ||
| WO-2024148216-A2 | Combination therapy with t cell engager | Inactive | 05-Jan-2023 | ||
| WO-2024148216-A3 | Combination therapy with t cell engager | Inactive | 05-Jan-2023 | ||
| WO-2023288056-A2 | Compositions and methods for expansion of hla-e-restricted t cell populations | Inactive | 15-Jul-2021 | ||
| WO-2023288056-A3 | Compositions and methods for expansion of hla-e-restricted t cell populations | Inactive | 15-Jul-2021 | C07K14/70539 |
NexImmune Signals
NexImmune ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
NexImmune FAQs
-
When was NexImmune founded?
NexImmune was founded in 2011.
-
Where is NexImmune headquartered?
NexImmune is headquartered in Gaithersburg, MD.
-
What is the size of NexImmune?
NexImmune has 72 total employees.
-
What industry is NexImmune in?
NexImmune’s primary industry is Drug Discovery.
-
Is NexImmune a private or public company?
NexImmune is a Private company.
-
What is NexImmune’s current revenue?
The current revenue for NexImmune is .
-
How much funding has NexImmune raised over time?
NexImmune has raised $185M.
-
Who are NexImmune’s competitors?
Marengo Therapeutics, Iovance Biotherapeutics, Parvus Therapeutics, Kite Pharma, and Sorrento Therapeutics are some of the 57 competitors of NexImmune.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process